Baird Medical Stock Price, News & Analysis

Baird Medical (NASDAQ: BDMD) concluded participation at the ACS Clinical Congress 2025 (October 5–7), showcasing its minimally invasive microwave ablation (MWA) systems to a global surgical audience.

At the exhibit, the company's advanced MWA technology drew significant surgeon interest across specialties, with live demonstrations focused on applications for thyroid nodules, breast disease, and other conditions. The company reported high engagement and renewed discussions with surgical and interventional leaders from leading institutions, and said it will pursue expanded U.S. and international partnerships building on congress momentum.

Baird Medical (NASDAQ: BDMD) is exhibiting at the American College of Surgeons Clinical Congress 2025 in Chicago from October 5–7, 2025. The company is at Booth 1061 presenting live, hands-on demonstrations of its minimally invasive Microwave Ablation (MWA) devices. Demonstrations highlight precision and efficiency for treating thyroid nodules, breast disease, and liver cancer, and aim to engage surgeons and clinical leaders on expanding MWA applications in interventional medicine. Participation underscores Baird Medical's focus on clinical collaboration and advancing patient care through its MWA technology.

Baird Medical (NASDAQ: BDMD) has successfully conducted physician training programs for its Microwave Ablation (MWA) technology at leading U.S. medical centers. The company hosted intensive training sessions at Tulane University and Columbia University to enhance clinical proficiency in thyroid nodule treatment.

At Tulane University, Dr. Emad Kandil led training through five live cases for specialists from multiple institutions. At Columbia University, Dr. Jennifer Kuo conducted specialized courses in May and August, demonstrating successful ablation of large thyroid nodules. The initiative aims to establish MWA as a leading treatment option for thyroid disease.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, showcased its innovations at the 2025 American Thyroid Association Annual Meeting. The company's exhibition featured live demonstrations of their MWA systems and attracted physicians from the U.S., Europe, and South America.

A highlight was the Expo Theater session featuring Dr. Emad Kandil from Tulane University, who presented data from over 200 MWA procedures. Notably, the presentation included evidence of MWA's effectiveness in 19 patients where previous Radiofrequency Ablation (RFA) treatments had failed. Dr. Kandil endorsed MWA as a safe and effective treatment for both benign and malignant thyroid nodules across adult and pediatric populations.

Baird Medical (NASDAQ: BDMD) participated in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES) from May 17-19, 2025, in Milwaukee, Wisconsin. The company, specializing in Microwave Ablation (MWA) technology, showcased its innovative MWA system for thyroid nodule treatment at the event.

The presentation highlighted the system's advantages as a minimally invasive alternative to traditional surgery, including reduced procedural risks, preserved thyroid function, and faster recovery times. The company engaged with attending surgeons to gather feedback on practical aspects such as patient selection, ultrasound guidance optimization, and various application scenarios.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, hosted an advanced training session and academic exchange in New Orleans. The program featured collaboration between Dr. Emad Kandil, Professor at Tulane University School of Medicine, and Dr. Gregory Randolph, Professor at Harvard Medical School and Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology.

During the May 9, 2025 event, the experts engaged in academic discussions on thyroid-focused topics, conducted clinical observations, and performed hands-on procedures. The initiative is part of Baird Medical's strategy to promote excellence in thyroid care through partnerships with medical leaders and support global adoption of minimally invasive therapies.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, announces its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES). The event will take place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin.

The AAES Annual Meeting, North America's premier gathering of endocrine surgeons, focuses on advancing endocrine surgery through research presentations, expert panels, and discussions on thyroid diseases, parathyroid, adrenal glands, and endocrine pancreas. Baird Medical's participation underscores the importance of its MWA technology in minimally invasive treatments for endocrine conditions, particularly thyroid nodules.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, has announced its participation in the 2025 Combined Otolaryngology Spring Meetings (COSM) scheduled for May 14-18, 2025, in New Orleans, Louisiana.

COSM is a prestigious international gathering for the otolaryngology-head and neck surgery community, bringing together multiple leading societies. The conference provides Baird Medical with a strategic platform to showcase its MWA technology portfolio and engage with key opinion leaders, clinicians, researchers, and potential strategic partners in the otolaryngology field.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, hosted an advanced MWA training session in New Orleans. The program was led by Dr. Emad Kandil, Professor at Tulane University School of Medicine, training Dr. Shahzad Ahmad, an endocrinologist and thyroid specialist from Salt Lake City.

During the session, Dr. Ahmad, who serves as Treasurer of the North American Society of Interventional Endocrinology (NASOIE), observed four live MWA procedures and participated in hands-on training. The program concluded with discussions on implementing MWA across clinical settings and the awarding of a Certificate of Completion.